ClinicalTrials.gg
CompletedNCT07071610Updated Jan 14, 2026

A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis

A Phase 2 interventional study of LNK01004 ointment 0.3% and LNK01004 ointment 1.0% in Atopic Dermatitis, sponsored by Lynk Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Lynk Pharmaceuticals Co., Ltd · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
145th of 191
75 · median 163
Started
2025
with 33 others
Phase 2
58 of 207
16 open now
Registered
155th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 145th largest by enrollment of the 191 interventional ones that give a count, is one of 34 that started in 2025, is one of 58 in phase 2, and was the 155th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of two concentrations (0.3 percent [%] and 1%) of twice daily LNK01004 ointment for the topical treatment in adult subjects with atopic dermatitis. This is a multicenter, randomized, double-blind, vehicle-controlled, 3-arm, parallel-group, dose-finding study in adult subjects with atopic dermatitis. Two concentrations of LNK01004 ointment (0.3% and 1%) and a vehicle control ointment will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) twice daily (morning and evening) for 8 weeks.

This study will consist of 3 periods: up to 4 weeks screening, 8 weeks double-blind treatment, and 2 weeks post-treatment follow-up.

Approximately 75 subjects (25 subjects for each group) with moderate to severe AD will be enrolled overall.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 65 years at screening.
  • Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for at least 3 months at screening.
  • Stable course of AD (not spontaneously improving or rapidly deteriorating) as determined by the investigator in the 3 weeks before screening.
  • IGA score of 3 to 4 at screening and baseline.
  • BSA of AD involvement, excluding the Scalp, Palms, and Soles, of 5% to 35% at screening and baseline.
  • Willingness to avoid pregnancy or fathering children based on the criteria as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would pose a significant risk to the participant or interfere with the interpretation of study data.
  • Concurrent conditions and history of:

    • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Baseline.
    • Active acute bacterial, fungal, or viral skin infection within 1 week before Baseline.
    • Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesion.
    • Any other concomitant non-skin disorder with the treatment that may interfere with the evaluation of AD.
  • Use of any of the following treatments within the indicated period before Baseline:

    • 6 weeks: Dupilumab
    • 5 half-lives or 12 weeks, whichever is longer: biologic agents (except dupilumab).
    • 4 weeks: Janus kinase (JAK) inhibitors.
    • 5 half-lives or 4 weeks, whichever is longer: Systemic therapy for AD, including but not limited to , methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE4)-inhibitors, Ultraviolet (UV) light therapy, or traditional Chinese medicine.
    • 2 weeks: Sedating antihistamines.
    • 1 week: Topical AD treatments (except topical emollient treatments), including but not limited to TCS, TCIs, or topical PDE-4 inhibitors.
  • surface antigen (HBs Ag) positive (+); ribonucleic acid (RNA) detectable in any subject with anti-HCV antibody (HCV Ab); (HIV) positive (+).
  • Participants with the following hematologic abnormalities at screening:

    • or AST ≥ 2 ×
    • TBiL ≥ 2 × ULN
    • Creatinine ≥ 1.5 × ULN
  • History of alcoholism or drug addiction within 6 months before screening or current alcohol or drug use.
  • Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before Baseline with another medication or current enrollment in another investigational drug protocol.
  • Participants who are pregnant, nursing, or planning a pregnancy during the study period.
  • Participants with known allergies to components or of the test drug.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Placebo comparator
    Vehicle

    Participants applied vehicle ointment BID for 8 weeks in DB period.

    Drug: Vehicle

  • Experimental
    LNK01004 ointment 0.3%

    Participants applied LNK01004 ointment 0.3% BID for 8 weeks in DB period.

    Drug: LNK01004 ointment 0.3%

  • Experimental
    LNK01004 ointment 1.0%

    Participants applied LNK01004 ointment 1.0% BID for 8 weeks in DB period.

    Drug: LNK01004 ointment 1.0%

Interventions

  • DrugLNK01004 ointment 0.3%

    LNK01004 ointment 0.3% BID

  • DrugLNK01004 ointment 1.0%

    LNK01004 ointment 1.0% BID

  • DrugVehicle

    vehicle BID

06

What researchers measure

Primary outcomes

  1. Mean Percentage Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 8

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 regions of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline to week 8

Secondary outcomes

  1. Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 8

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 regions of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline to week 8

  2. Percentage of Participants Who Achieve a ≥ 75% Improvement From Baseline in EASI (EASI-75) at Week 8

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 regions of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline to week 8

  3. Percentage of Participants Who Achieve a ≥ 90% Improvement From Baseline in EASI (EASI-90) at Week 8

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 regions of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline to week 8

  4. Percentage of Participants Who Achieve a ≥ 50% Improvement From Baseline in EASI (EASI-50) at Week 2

    EASI is a validated composite scoring system integrating the proportion of the body region (area) involved and the intensity of key signs of atopic dermatitis (AD). The EASI score examines 4 regions of the body and weights them for participants 8 years of age and older as follows: Head/Neck (H) = 0.1, Upper limbs (UL) = 0.2, Trunk (T) = 0.3, and Lower limbs (LL) = 0.4. Then, the area affected is scored from 0 (0% involvement) to 6 (90-100% involvement). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The total EASI score ranges from 0 to 72. A higher score indicated worse disease status, and a negative change from baseline indicated improvement.

    Time frame: Baseline to week 2

  5. Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 to 1 Who Have an Improvement of ≥ 2 Points at Week 8

    IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). An IGA responder was defined as a participant achieving an IGA score of 0 to 1 and an IGA score improvement at least 2 from baseline.

    Time frame: Baseline to week 8

  6. Percentage of Participants Achieving ≥4-Point Improvement in WI-NRS Pruritus Score at Week 8

    The number of participants achieving a ≥4-point improvement from Baseline in WI-NRS score is presented. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Higher scores indicate greater symptom severity.

    Time frame: Baseline to week 8

  7. Number of Participants with Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. TEAEs were defined as any AEs with an onset date during or after the first study treatment dose.

    Time frame: Baseline to week 10

  8. Plasma Concentration of LNK01004

    Time frame: week 4,week 8

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No — This is due to proprietary and regulatory considerations. The data will remain confidential to protect intellectual property and participant privacy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jul 2025, 4 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 4 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 17, 2025
StartActual
Mar 18, 2025
Primary completionActual
Jul 24, 2025
CompletionActual
Jul 24, 2025
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071610
Lead sponsor
Lynk Pharmaceuticals Co., Ltd
Responsible party
Sponsor
First posted
Jul 17, 2025
Start date
Mar 18, 2025
Primary completion
Jul 24, 2025
Completion
Jul 24, 2025
Last update
Jan 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion